Christine Megerdichian Parseghian, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses overcoming acquired resistance to anti-EGFR therapies. A study was conducted on acquired resistance mutations occurring within the first- or third-line setting via the investigation of plasma samples from three large Phase III trials. Patients being treated in the third-line setting had significantly higher rates of acquired resistance mutations than those treated in the first-line. Additionally, patients who were being treated with chemotherapy plus anti-EGFR had significantly lower rates of acquired mutations compared to patients treated with anti-EGFR monotherapy. These findings raise implications on how best to overcome both acquired genomic and transcriptomic resistance to anti-EGFR therapies. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
